AVN-397
Drug possibly to treat Alzheimer's disease
None
AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD). [1] [2] Avineuro announced that it would start Phase II clinical trials in 2009, and those trials are ongoing as of 2012. [3] [4] [5]
References
- ↑ Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery" . Nature Reviews Drug Discovery . 12 (9): 667–687. doi : 10.1038/nrd4075 . ISSN 1474-1776 . PMC 4176700 . PMID 23989795 . S2CID 6531810 .
- ↑ "AVN 397 - AdisInsight" . adisinsight.springer.com . Retrieved 2023-03-12 .
- ↑ "Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease" . BioSpace . Retrieved 2023-03-12 .
- ↑ "Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014" . docksci.com . S2CID 998047 . Retrieved 2023-03-12 .
- ↑ Medicines in Development / Mental Illnesses / 2012 Report (PDF) , archived (PDF) from the original on 9 Jul 2022
This drug article relating to the nervous system is a stub . You can help Wikipedia by expanding it . |